Eisai Co., Ltd. (ESAIY)
OTCMKTS · Delayed Price · Currency is USD
7.78
-0.02 (-0.26%)
Aug 28, 2025, 3:35 PM EDT
Eisai Employees
Eisai had 10,917 employees as of March 31, 2025. The number of employees decreased by 150 or -1.36% compared to the previous year.
Employees
10,917
Change (1Y)
-150
Growth (1Y)
-1.36%
Revenue / Employee
$509,835
Profits / Employee
$31,951
Market Cap
8.81B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 10,917 | -150 | -1.36% |
| Mar 31, 2024 | 11,067 | -9 | -0.08% |
| Mar 31, 2023 | 11,076 | -246 | -2.17% |
| Mar 31, 2022 | 11,322 | 85 | 0.76% |
| Mar 31, 2021 | 11,237 | 239 | 2.17% |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Tian'an Technology Group | 8 |
| Glass House Brands | 374 |
| Elite Pharmaceuticals | 68 |
| CytoDyn | 13 |
| Northwest Biotherapeutics | 25 |
| American Oncology Network | 1,914 |
| Silence Therapeutics | 116 |
| Jushi Holdings | 1,234 |
Eisai News
- 23 days ago - Eisai Co., Ltd. (ESALF) Q1 2026 Earnings Call Transcript - Seeking Alpha
- 4 weeks ago - Patients still benefit from Eisai and Biogen Alzheimer's drug after four years, study finds - Reuters
- 2 months ago - Eisai: Leqembi Approved In EU (Rating Downgrade) - Seeking Alpha
- 3 months ago - Eisai Co., Ltd. (ESALF) Q4 2025 Earnings Call Transcript - Seeking Alpha
- 4 months ago - EU authorizes Eisai-Biogen's drug for treatment of early Alzheimer's disease - Reuters
- 6 months ago - EU regulator not updating opinion on Eisai-Biogen's Alzheimer's drug - Reuters
- 6 months ago - Eisai: Will Have No Problem Hitting Leqembi Forecasts - Seeking Alpha
- 7 months ago - Eisai Co., Ltd. (ESALF) Q3 2024 Earnings Call Transcript - Seeking Alpha